- The Boehringer Ingelheim Venture Fund (BIVF) extends its investment focus to include regenerative medicine, infectious diseases and digital health
- BIVF increases its presence in the United States and adds new staff members
- Through its successful investments in immune-oncology, the BIVF has helped the company elevate its presence across the global healthcare ecosystem and establish a new focus area
INGELHEIM, Germany & BOSTON--(BUSINESS WIRE)--Boehringer Ingelheim today announced an increase in funding for its corporate venture fund, known as the Boehringer Ingelheim Venture Fund (BIVF), from EUR 100 to 250 million. The additional funds will be used to invest in promising early stage start-up companies, focusing on regenerative medicine, infectious diseases and immune oncology among others, as well as growing the portfolio in the U.S. and opening doors for the BIVF in digital health. The significant additional funding goes along with a doubling of the number of investment managers.
Boehringer Ingelheim Corporate Center GmbH
Dr. Reinhard Malin
Head of Communications Innovation Unit
Media + PR
P: +49 6132 77-90815 :: M: + 49 151 150 20 690
Boehringer Ingelheim Pharmaceuticals, Inc.
Associate Director, Media and Corporate Reputation
P: +1 203 791-6672 :: M: +1 203-957-5114